<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514159</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c5-003</org_study_id>
    <nct_id>NCT04514159</nct_id>
  </id_info>
  <brief_title>A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer</brief_title>
  <official_title>A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeno Alpha Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeno Alpha Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in&#xD;
      combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor&#xD;
      positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive the same treatment but ZN-c5 will be given at different doses in this dose escalation study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events from ZN-c5 in combination with abemaciclib</measure>
    <time_frame>Through study completion, anticipated to be 21 months</time_frame>
    <description>Measured by the number of treatment-emergent adverse events and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine tumor responses to combination treatment</measure>
    <time_frame>Through study completion, anticipated to be 21 months</time_frame>
    <description>Measured by radiographic responses as defined by revised Response Evaluation Criteria in Solid Tumor (RECIST) v1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ZN-c5 + abemaciclib combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take abemaciclib (150mg) orally twice a day and ZN-c5 (dose escalation) orally once or twice a day to determine the safety, tolerability, and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c5</intervention_name>
    <description>ZN-c5 is the study drug.</description>
    <arm_group_label>ZN-c5 + abemaciclib combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Abemaciclib (VERZENIO®) is an approved drug.</description>
    <arm_group_label>ZN-c5 + abemaciclib combination therapy</arm_group_label>
    <other_name>VERZENIO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years of age&#xD;
&#xD;
          -  Women can be peri- or postmenopausal, as defined by at least one of the following:&#xD;
&#xD;
               -  Age ≥ 60 years;&#xD;
&#xD;
               -  Age &lt; 60 years and cessation of regular menses for at least 12 consecutive months&#xD;
                  with no alternative pathological or physiological cause; and serum estradiol and&#xD;
                  follicle-stimulating hormone (FSH) level within the laboratory's reference range&#xD;
                  for postmenopausal females;&#xD;
&#xD;
               -  Documented bilateral oophorectomy;&#xD;
&#xD;
               -  Must receive a gonadotrophin-releasing hormone agonist beginning at least 4 weeks&#xD;
                  prior to the first dose of study medication&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced adenocarcinoma of the&#xD;
             breast&#xD;
&#xD;
          -  Estrogen receptor positive disease&#xD;
&#xD;
          -  Human Epidermal Growth Factor Receptor 2 negative disease&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy within the following windows:&#xD;
&#xD;
               -  Tamoxifen, aromatase inhibitor, fulvestrant, or other anti-cancer endocrine&#xD;
                  therapy &lt; 14 days;&#xD;
&#xD;
               -  Any investigational drug therapy &lt; 28 days or 5 half-lives (whichever is shorter)&#xD;
&#xD;
               -  Any prior systemic chemotherapy regardless of the stop date, but the subject must&#xD;
                  have recovered to eligibility levels from prior toxicity&#xD;
&#xD;
          -  Prior treatment with CDK4/6 inhibitors&#xD;
&#xD;
          -  Unexplained symptomatic endometrial disorders (including, but not limited to,&#xD;
             endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Voliotis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zeno Alpha Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitris Voliotis, MD</last_name>
    <phone>+1 212.433.3787</phone>
    <email>dvoliotis@zentalis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Kraków</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose escalation</keyword>
  <keyword>Phase 1 combination</keyword>
  <keyword>Selective estrogen receptor degrader</keyword>
  <keyword>Hormone sensitive</keyword>
  <keyword>Estrogen receptor</keyword>
  <keyword>Hormone receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

